Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Rhythm · Phase 3 · Completed · Enrollment 52

NCT03746522

EudraCT 2018-004058-11

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

≥5%
32.3
≥10%
≥15%
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
Setmelanotide (Double-Blind)n/rn/rn/rn/r
Placebo (Double-Blind)n/rn/rn/rn/r
Setmelanotide (Open-label)n/rn/rn/rn/r
Pivotal Cohortn/r32.3%n/rn/r

Not shown

  • Setmelanotide (Double-Blind): endpoint not reported
  • Placebo (Double-Blind): endpoint not reported
  • Setmelanotide (Open-label): endpoint not reported